{"id":9606,"date":"2021-03-03T10:57:16","date_gmt":"2021-03-03T09:57:16","guid":{"rendered":"https:\/\/ggba.swiss\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/"},"modified":"2023-07-04T13:43:33","modified_gmt":"2023-07-04T11:43:33","slug":"debiopharm-signe-contrat-de-plus-de-e-900-millions-merck","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/","title":{"rendered":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck"},"content":{"rendered":"

Debiopharm<\/a>, une soci\u00e9t\u00e9 biopharmaceutique mondiale install\u00e9e au c\u0153ur de la Health Valley<\/a>, a annonc\u00e9 la signature d’un accord de licence exclusif avec le g\u00e9ant pharmaceutique Merck<\/a>, pour le d\u00e9veloppement et la commercialisation du Xevinapant.<\/p>\n

Le Xevinapant<\/a> est un nouveau m\u00e9dicament en cours de d\u00e9veloppement pour le traitement des cancers de la t\u00eate et du cou. Selon Debiopharm, ce nouveau m\u00e9dicament \u00ab\u00a0a montr\u00e9 des r\u00e9sultats exceptionnels lors de tests cliniques, notamment men\u00e9s au CHUV\u00a0\u00bb. Au cours de cette phase, une r\u00e9duction de 51% du risque de d\u00e9c\u00e8s a \u00e9t\u00e9 observ\u00e9e chez les patients ayant \u00e9t\u00e9 suivis pendant trois ans, en comparaison \u00e0 ceux qui n’ont pas re\u00e7u ce traitement.<\/p>\n

Cet accord de licence mondial est un accomplissement significatif qui r\u00e9compense les efforts de d\u00e9veloppement clinique men\u00e9s par Debiopharm tout en d\u00e9montrant l’agilit\u00e9 et la pertinence du mod\u00e8le commercial sp\u00e9cifique et unique de la soci\u00e9t\u00e9.<\/p>\n

Selon les termes de l’accord de licence, Merck obtient les droits exclusifs de d\u00e9veloppement et de commercialisation de Xevinapant au niveau mondial, et Debiopharm recevra un acompte de EUR 188 millions d’euros et jusqu’\u00e0 EUR 710 millions d’euros en versements \u00e9chelonn\u00e9s, ainsi qu\u2019une commission sur les ventes.<\/p>\n

Le Xevinapant, qui est utilis\u00e9 en combinaison avec la chimioradioth\u00e9rapie, va \u00e0 pr\u00e9sent passer \u00e0 un essai mondial de phase III impliquant 700 patients, une phase qui sera cofinanc\u00e9e par Merck et Debiopharm.<\/p>\n

Install\u00e9e \u00e0 Lausanne, dans le canton de Vaud, et \u00e0 Martigny, dans le canton du Valais, Debiopharm d\u00e9veloppe des th\u00e9rapies innovantes qui ciblent les besoins m\u00e9dicaux non satisfaits en oncologie et en maladies infectieuses. Le dernier produit de la soci\u00e9t\u00e9, Xevinapant, est bien plac\u00e9 pour devenir la troisi\u00e8me th\u00e9rapie transformatrice d\u00e9velopp\u00e9e par Debiopharm dans le domaine de l’oncologie.<\/p>\n","protected":false},"excerpt":{"rendered":"

Debiopharm a accord\u00e9 une licence mondiale exclusive au g\u00e9ant pharmaceutique Merck pour le d\u00e9veloppement et la commercialisation de son m\u00e9dicament Xevinapant pour le traitement des cancers de la t\u00eate et du cou.<\/p>\n","protected":false},"author":3,"featured_media":9607,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1065,1069,1072],"class_list":["post-9606","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-oncology-fr","tag-pharma-fr","tag-rd-fr"],"acf":[],"yoast_head":"\nDebiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Debiopharm a accord\u00e9 une licence mondiale exclusive au g\u00e9ant pharmaceutique Merck pour le d\u00e9veloppement et la commercialisation de son m\u00e9dicament Xevinapant pour le traitement des cancers de la t\u00eate et du cou.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T09:57:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:43:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck\",\"datePublished\":\"2021-03-03T09:57:16+00:00\",\"dateModified\":\"2023-07-04T11:43:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\"},\"wordCount\":328,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg\",\"keywords\":[\"Oncology\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\",\"name\":\"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg\",\"datePublished\":\"2021-03-03T09:57:16+00:00\",\"dateModified\":\"2023-07-04T11:43:33+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/","og_locale":"fr_FR","og_type":"article","og_title":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area","og_description":"Debiopharm a accord\u00e9 une licence mondiale exclusive au g\u00e9ant pharmaceutique Merck pour le d\u00e9veloppement et la commercialisation de son m\u00e9dicament Xevinapant pour le traitement des cancers de la t\u00eate et du cou.","og_url":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2021-03-03T09:57:16+00:00","article_modified_time":"2023-07-04T11:43:33+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck","datePublished":"2021-03-03T09:57:16+00:00","dateModified":"2023-07-04T11:43:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/"},"wordCount":328,"image":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg","keywords":["Oncology","Pharma","R&D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/","url":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/","name":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg","datePublished":"2021-03-03T09:57:16+00:00","dateModified":"2023-07-04T11:43:33+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/Merck-Debio-630x380-3.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/debiopharm-signe-contrat-de-plus-de-e-900-millions-merck\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Debiopharm signe un contrat de plus de EUR 900 millions avec Merck"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=9606"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9606\/revisions"}],"predecessor-version":[{"id":17890,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9606\/revisions\/17890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/9607"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=9606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=9606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=9606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}